The 11 most recent market catalysts affecting $IMNN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 85
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
IMUNON reported final overall survival results from its randomized Phase 2 OVATION 2 Study for IMNN-001 in advanced ovarian cancer, which are highlighted as positive. This is a cru…
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 65
IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
IMUNON announced that the Independent Data Monitoring Committee (IDMC) for its IMNN-001 Phase 2 study recommended continuing the trial without modification, citing no new safety si…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001
IMUNON has secured a CRADA with the NCI, a significant development for its lead immunotherapy candidate, IMNN-001. This partnership provides IMUNON with access to NCI's resources f…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day
IMUNON is holding an R&D Day to discuss its IMNN-001 immunotherapy, specifically focusing on the OVATION 1 clinical study and featuring insights from a trial participant and leadin…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 65
Watching Imunon; Zacks Small-Cap Research Gives Stock $25 Price Valuation
The headline suggests a positive catalyst for Imunon (IMNN) due to Zacks Small-Cap Research assigning a $25 price valuation. This could generate immediate buying interest and a pot…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
IMUNON Announces Its Phase 3 OVATION 3 Trial Of IMNN-001 In Patients With Ovarian Cancer Has Observed Rapid Site Activation And Above-Forecast Enrollment Rate
IMUNON announced that its Phase 3 OVATION 3 trial for IMNN-001 in ovarian cancer is experiencing rapid site activation and an enrollment rate significantly exceeding initial foreca…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 85
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
Imunon's announcement of accelerated enrollment and strong safety data for its pivotal Phase 3 ovarian cancer trial is a significant positive catalyst. The faster-than-expected tri…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
EXCLUSIVE: Imunon Says Enrollment Momentum for Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Exceeds Expectations; Projects Enrollment to Complete in Q2 of 2029
The headline signals strong operational execution by Imunon, as exceeding enrollment expectations for a Phase 3 trial is a critical de-risking event in drug development. This accel…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 65
IMUNON To Present New Data On IMNN-001, DNA-Based Interleukin-12 Immunotherapy For Advanced Ovarian Cancer, At Inaugural AACR Conference On Drug Discovery And Development
IMUNON is presenting new data on its lead immunotherapy candidate, IMNN-001, for advanced ovarian cancer at a prominent new AACR conference. This event provides a significant platf…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 75
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon Inc. (IMNN) released preliminary Phase 2 data for IMNN-001 in advanced ovarian cancer, demonstrating lower rates of residual disease and higher ctDNA clearance when combined…
Jul 21, 2026
Corporate Catalyst
Bullish
Impact 95
EXCLUSIVE: Imunon Says Phase 2 IMNN-001 Data Showed Lower MRD, Higher ctDNA Clearance And Favorable Safety In Frontline Ovarian Cancer; Preliminary Data Reinforces Immunotherapy’s Potential For Success In Currently Recruiting Phase 3 OVATION 3 Study
The exclusive release of positive Phase 2 data for IMNN-001 in frontline ovarian cancer is a significant de-risking event for Imunon. Lower MRD (Minimal Residual Disease) and highe…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.